Glucotrack, Inc. (GCTK) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US45824Q8042

Price
0.22 USD
Market cap
220,909.69 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Glucotrack, Inc. financials

Fiscal year2025
Operating income-16.09 m USD
EBIT-19.39 m USD
Net income-19.39 m USD
Diluted EPS – continuing operations31.22 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Glucotrack, Inc.

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.